Treating HIV-Associated Lymphoma
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
Clinical Pearls
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
- The most appropriate way to treat patients with HIV and lymphoma has been a quandary for years.
- This study looked at autologous hematopoietic stem cell transplantation for the treatment of patients with chemotherapy-sensitive, relapsed/refractory HIV-associated lymphoma.
- Estimated probability of one-year OS was 86.6%.
<<<
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
